期刊文献+

慢性髓细胞性白血病与血管生成因子关系 被引量:4

Relationship of chronic myelocytic leukemia and angiogenesis factors
下载PDF
导出
摘要 目的 :了解血管生成因子在慢性髓细胞性白血病 (CML)患者中的分泌和基因表达 ,初步探讨血管生成在CML发病和发展中的作用。方法 :用ELISA方法检测CML患者和对照组外周血血管内皮细胞生长因子 (VEGF)浓度 ,取骨髓组织活检 ,用CD34单抗标记检测骨髓微血管密度 (MVD) ,同时取外周血和骨髓细胞 ,采用RT PCR法检测VEGF、b FGF基因表达。结果 :研究组外周血VEGF浓度 (177.5 3± 15 3.4 5pg/ml)明显高于对照组 (73.12± 19.82pg/ml) (P <0 .0 5 ) ,差别有统计学意义。骨髓细胞和外周血RT PCR检测结果基本吻合 ,没有受到骨髓中其他细胞的干扰。研究组VEGF和b FGF基因高表达 (P <0 .0 5 ) ,两组差别有统计学意义。结论 :CML与血管生成之间存在着明显的关系 。 Purpose:To study the secretion and gene expression of Angiogenesis factors in the patients with CML and study the effect of Angiogenesis in the occurrence and development of CML. Methods:Concentration of VEGF in peripheral blood was determined by using ELISA. Myeloid tissue was extracted from all CML cases and ITP patients to detect MVD by using CD34 labelling. At the same time the level of VEGF,b-FGF were detected by using RT-PCR in both peripheral blood and myeloid cells.Results:Our results showed that the concentration of VEGF was obviously higher in the peripheral blood of CML patients(177.53±153.45 pg/ml) than in those of control group(73.12±19.82 pg/ml). The gene expression of VEGF and b-FGF were both higher than those of control group. The difference has statistical significance(P<0.05).Conclusions:We can demonstrate a marked relation between CML and angiogenesis.Anti-angiogenesis therapy maybe an effective method to treat CML.[
出处 《中国癌症杂志》 CAS CSCD 2004年第5期462-465,共4页 China Oncology
关键词 慢性髓细胞性白血病 血管生成 血管内皮细胞生长因子 微血管密度 chronic myelocytic leukemia angiogenesis microvessel density vascular endothelial growth factor
  • 相关文献

参考文献9

  • 1Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte plateletand monocyte/macrophage[J].Am J Med,1977,63(1):125-130.
  • 2Strife A, Clarkson B. Biology of chronic myelogenous leukemia: is discordant maturation the primary defect[J].Semin Hematol,1988,25(1):1-19.
  • 3Folkman J. Tumor angiogenesis: therapeutic implications[J].N Engl J Med,1971,18,285(21):1182-1186.
  • 4Brem S, Brem H, Folkman J, et al. Prolonged tumor dormancy by prevention of neovascularization in the vitreous[J].Cancer Res, 1976,36(8):2807-2812.
  • 5Bussolino F, Albini A, Camussi G, et al. Role of soluble mediators in angiogenesis[J].Eur J Cancer, 1996,32A(14):2401-2412.
  • 6Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent[J].J Biol Chem,1996,12,271(2):603-606.
  • 7Toi M, Taniguchi T,YamamotoY, et al.Clinical significance of the determination of angiogenic factors[J].Eur J Cancer,1996,32A(14):2513-2519.
  • 8Alvaro A, Hagop K, Taghi M,et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes[J].Blood,2000,15,96(6):2240-2245.
  • 9William TB, Lynne R, Yvette F, et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies[J].Cancer Res,1999,1,59(3):728-733.

同被引文献87

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部